Adverum Biotechnologies, Inc.

NasdaqCM ADVM

Adverum Biotechnologies, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024

Adverum Biotechnologies, Inc. Return on Capital Employed (ROCE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Adverum Biotechnologies, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -58.74%.
Adverum Biotechnologies, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -31.51%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqCM: ADVM

Adverum Biotechnologies, Inc.

CEO	Dr. Laurent Fischer
IPO Date	July 31, 2014
Location	United States
Headquarters	800 Saginaw Drive
Employees	121
Sector	Healthcare
Industries Biotechnology Eyewear Pharmaceuticals

Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Key trends

Past 5 years